Novo Nordisk partners with OpenAI

The multi-year agreement will give Novo Nordisk employees access to OpenAI's most sophisticated models to identify promising new drug candidates more efficiently.

By leveraging agentic AI, the Danish drugmaker hopes to reduce the time and cost associated with early-stage clinical research.

The move comes as competition in the weight-loss drug market intensifies, with rivals also racing to adopt AI-driven technologies.

OpenAI stated that the partnership represents a significant step in applying generative AI to solve critical challenges in healthcare and life sciences.